MYRIAD GENETICS INC

MYRIAD GENETICS INC Share · US62855J1043 · MYGN · 897518 (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of MYRIAD GENETICS INC
Analyst Grade Summary
gauge-img
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
0
8
22
6
0
No Price
01.05.2026 20:00
Current Prices from MYRIAD GENETICS INC
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
MYGN
USD
01.05.2026 20:00
4,80 USD
0,05 USD
+1,05 %
IEXG: IEX
IEX
MYGN
USD
01.05.2026 19:59
4,80 USD
0,05 USD
+1,05 %
XLON: London
London
0K3W.L
USD
01.05.2026 14:17
4,89 USD
0,14 USD
+2,95 %
XDUS: Düsseldorf
Düsseldorf
MGIRSD43.DUSB
EUR
30.04.2026 17:31
4,01 EUR
-0,34 EUR
-7,84 %
XHAN: Hannover
Hannover
MGIRSD43.HANB
EUR
30.04.2026 15:25
4,05 EUR
-0,30 EUR
-6,81 %
XHAM: Hamburg
Hamburg
MGIRSD43.HAMB
EUR
30.04.2026 15:25
4,05 EUR
-0,30 EUR
-6,81 %
XDQU: Quotrix
Quotrix
MGIRSD43.DUSD
EUR
30.04.2026 05:27
3,99 EUR
-
Share Float & Liquidity
Free Float 93,17 %
Shares Float 87,12 M
Shares Outstanding 93,51 M
Invested Funds

The following funds have invested in MYRIAD GENETICS INC:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
93,30
Percentage (%)
0,22 %
Company Profile for MYRIAD GENETICS INC Share
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Company Data

Name MYRIAD GENETICS INC
Company Myriad Genetics, Inc.
Symbol MYGN
Website https://myriad.com
Primary Exchange XNAS NASDAQ
WKN 897518
ISIN US62855J1043
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Samraat S. Raha
Market Capitalization 431 Mio
Country United States of America
Currency USD
Employees 2,7 T
Address 320 Wakara Way, 84108 Salt Lake City
IPO Date 2018-01-29
Dividends from 'MYRIAD GENETICS INC'
Ex-Date Dividend per Share
15.03.2022 0,29 USD
01.07.2009 1,75 USD
15.06.2009 1,75 USD

Stock Splits

Date Split
26.03.2009 2:1
12.09.2000 2:1

Ticker Symbols

Name Symbol
Düsseldorf MGIRSD43.DUSB
Frankfurt MYD.F
Hamburg MGIRSD43.HAMB
Hannover MGIRSD43.HANB
London 0K3W.L
NASDAQ MYGN
Quotrix MGIRSD43.DUSD
More Shares
Investors who hold MYRIAD GENETICS INC also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
CARMAT            EO -,04
CARMAT EO -,04 Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
GUARDANT HEALTH INC
GUARDANT HEALTH INC Share
ILLUMINA INC
ILLUMINA INC Share
INTEL CORP
INTEL CORP Share
MICROSOFT CORP
MICROSOFT CORP Share
NEWMONT 19/29
NEWMONT 19/29 Bond
PROCTER GAMBLE CORP
PROCTER GAMBLE CORP Share
VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INC Share
VIRG.EL.PWR 20/50
VIRG.EL.PWR 20/50 Bond
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share